Literature DB >> 7585145

Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity.

L D Falo1, M Kovacsovics-Bankowski, K Thompson, K L Rock.   

Abstract

Cytotoxic T lymphocytes (CTLs) kill neoplastic or virally infected cells after recognizing on their surface antigenic peptides bound to major histocompatibility complex class I molecules. These peptides are derived from antigens that are degraded in the cytosol of the affected cell. Because exogenous proteins cannot enter the cytosol, immunizations with killed pathogens or their proteins do not generally elicit CTLs. However, antigens that are internalized into phagocytic cells can enter the cytosol and be processed for class I presentation. Here we show that immunization with a purified antigen on an avidly phagocytized particle primes CTLs, which in turn protect animals from subsequent challenge with tumours transfected with the antigen gene. Interestingly, these animals also become immune to other antigens expressed by the tumour. This approach could be exploited to develop tumour and viral vaccines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585145     DOI: 10.1038/nm0795-649

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  76 in total

1.  Cellular protein is the source of cross-priming antigen in vivo.

Authors:  Lianjun Shen; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

2.  Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.

Authors:  Kamran Kafi; David J Betting; Reiko E Yamada; Michael Bacica; Kristopher K Steward; John M Timmerman
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

3.  Activation outcomes induced in naïve CD8 T-cells by macrophages primed via "phagocytic" and nonphagocytic pathways.

Authors:  Isabel María Olazabal; Noa Beatriz Martín-Cofreces; María Mittelbrunn; Gloria Martínez del Hoyo; Balbino Alarcón; Francisco Sánchez-Madrid
Journal:  Mol Biol Cell       Date:  2007-12-12       Impact factor: 4.138

4.  Polymer blend particles with defined compositions for targeting antigen to both class I and II antigen presentation pathways.

Authors:  Kenny K Tran; Xi Zhan; Hong Shen
Journal:  Adv Healthc Mater       Date:  2013-10-02       Impact factor: 9.933

5.  A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma.

Authors:  Xiaoping Zhang; Neng-Lian Li; Chao Guo; Ying-Dong Li; Lu-Lu Luo; Yong-Qi Liu; Yun-Yan Duan; Zhen-Dong Li; Xiao-Rong Xie; Hai-Xia Song; Li-Ping Yang; Fang-Yu An
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

6.  B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.

Authors:  Hiroshi Arima; Momoko Nishikori; Yasuyuki Otsuka; Wataru Kishimoto; Kiyotaka Izumi; Koubun Yasuda; Tomohiro Yoshimoto; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2018-09-25

7.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome.

Authors:  Weili Yan; Leaf Huang
Journal:  Int J Pharm       Date:  2008-10-15       Impact factor: 5.875

10.  A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation.

Authors:  Sharvan Sehrawat; Paul-Albert Koenig; Oktay Kirak; Christian Schlieker; Manuel Fankhauser; Hidde L Ploegh
Journal:  Blood       Date:  2012-12-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.